Ultragenyx Pharmaceutical Inc. reported its quarterly results for the period ending September 30, 2026, highlighting continued revenue growth from its commercialized products and ongoing investment in its clinical pipeline. The company maintained its focus on rare and ultra-rare disease treatments while managing operating expenses in line with strategic objectives.
Ultragenyx reported Q3 2026 total revenue of $173 million and a net loss of $118 million, while announcing a major restructuring plan to reduce its workforce by 20%. The company also confirmed the sale of two Priority Review Vouchers for $413 million and reaffirmed its 2026 revenue guidance and 2027 profitability targets.
Term
Q3 2026
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products. With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx
Ultragenyx Pharmaceutical CFO Howard Horn Sells $108K of Stock
Howard Horn, CFO, sold 7,066 shares of Ultragenyx Pharmaceutical Inc. at $15.27 a share, worth $108K in total on Oct 15, 2026. Shares held after the trade: 89,229 (-7.3%).
Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.